Burning Rock Biotech Limited
Price Action
Technical Summary
CONSOLIDATINGBurning Rock Biotech Limited is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 59), indicating performance broadly in line with the market. Earnings growth of 55% provides fundamental context to the price action. Investors should exercise caution due to high volatility (138% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $18.76 | -9.34% | BELOW |
| 50 SMA | $19.42 | -12.42% | BELOW |
| 100 SMA | $23.31 | -27.01% | BELOW |
| 150 SMA | $19.91 | -14.57% | BELOW |
| 200 SMA | $16.94 | +0.43% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BNR in an uptrend right now?
BNR has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BNR overbought or oversold?
BNR's RSI (14) is 42. The stock is in neutral territory, neither overbought nor oversold.
Is BNR outperforming the market?
BNR has a Relative Strength (RS) Rating of 59 out of 99. BNR is performing about average compared to the market.
Where is BNR in its 52-week range?
BNR is trading at $17.01, which is 41% of its 52-week high ($41.72) and 37% above its 52-week low ($2.26).
How volatile is BNR?
BNR has a Beta of 1.87 and 52-week volatility of 138%. It's more volatile than the S&P 500 - expect bigger swings.